Patient case (clinical description): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient's own account: I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Clinical trial: Evaluation of ADG20 for the Prevention of COVID-19

Eligibility criteria:
Inclusion Criteria:

          -  Tests negative for current or previous SARS-CoV-2 infection by RT PCR and serology
             (Pre-exposure population only)

          -  Is at high risk of SARS-CoV-2 infection as assessed by the Investigator:

               1. Post-exposure population: including, but not limited, to household contact or
                  occupational/recreational exposure to an individual with a diagnosis of
                  SARS-CoV-2 infection (index case). Note: Participants with recent exposure to a
                  laboratory-confirmed index case must be asymptomatic and randomized within 5 days
                  (120 hours) of collection of the index case's positive SARS-CoV-2 diagnostic
                  test.

               2. Pre-exposure population: Occupational, housing, recreational and/or social
                  conditions that are likely to increase risk of exposure to SARS-CoV-2.

          -  Agrees to defer receipt of COVID-19 vaccination for minimum of 180 days (6 months)
             after dosing

        Exclusion Criteria:

          -  Has received (1) a SARS-CoV-2 vaccine, (2) mAb or (3) convalescent plasma from a
             person who has recovered from COVID-19 or prior participation in SARS-CoV2 vaccine,
             convalescent plasma, or mAb clinical trial any time prior to participation in the
             study.

          -  Receipt of any investigational product within 30 days or 5 half lives before the day
             of enrollment.

          -  Is acutely ill or febrile 72 hours before or at Screening or has other COVID-19
             symptoms including cough, fatigue, muscle or body aches, headache, or loss of taste or
             smell. Fever is defined as a body temperature ≥38.0°C (≥100.4°F).

          -  Has received or plans to receive a non-COVID-19 vaccine within 28 days before or after
             dosing (except for seasonal influenza vaccine, which is not permitted within 14 days
             before or after dosing).

        NOTE: Other protocol defined inclusion/exclusion criteria apply
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Contradiction